Advertisement
UK markets closed
  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     
  • HANG SENG

    17,284.54
    +83.27 (+0.48%)
     
  • CRUDE OIL

    82.78
    -0.03 (-0.04%)
     
  • GOLD FUTURES

    2,340.90
    +2.50 (+0.11%)
     
  • DOW

    38,083.74
    -377.18 (-0.98%)
     
  • Bitcoin GBP

    51,503.46
    -449.33 (-0.86%)
     
  • CMC Crypto 200

    1,392.62
    +10.04 (+0.73%)
     
  • NASDAQ Composite

    15,573.92
    -138.83 (-0.88%)
     
  • UK FTSE All Share

    4,387.94
    +13.88 (+0.32%)
     

What Gilead Sciences’ Bottom Line Is Expected to Look Like in Q2

What Gilead Sciences’ Bottom Line Is Expected to Look Like in Q2

Gilead Sciences’ (GILD) selling, general, and administrative expenses are expected to increase 10.87%, from $827 million in Q2 2017 to $916.87 million in Q2 2018. Its research and development expenses are expected to increase 8.78%, from $812 million in Q2 2017 to $883.27 million in Q2 2018. Its expenses on stock-based compensation are expected to rise from $61 million in Q2 2017 to $194.33 million in Q2 2018.